このエントリーをはてなブックマークに追加
ID 52709
Sort Key
13
Title Alternative
Molecular targeted therapy in myeloma and lymphoma
FullText URL
Thumnail 126_143.pdf 1.33 MB
Author
Saeki, Kyosuke
Keywords
骨髄腫
リンパ腫
分子標的治療薬
Note
特集 (Feature Article)
Publication Title
岡山医学会雑誌
Published Date
2014-08-01
Volume
volume126
Issue
issue2
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
143
End Page
150
ISSN
0030-1558
NCID
AN00032489
Content Type
Journal Article
OAI-PMH Set
岡山大学
language
日本語
Copyright Holders
Copyright (c) 2014 岡山医学会
File Version
publisher
Refereed
True
DOI
NAID
Eprints Journal Name
joma
References
1) Cartron G, Watier H, Golay J, Solal-Celigny P : From the bench to the bedside : ways to improve rituximab efficacy. Blood (2004) 104, 2635-2642.
2) Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, et al. : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 346, 235-242.
3) Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilberg O : Rituximab maintenance for the treatment of patients with follicular lymphoma : systematic review and meta-analysis of randomized trials. J Natl Cancer Inst (2009) 101, 248-255.
4) Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, et al. : Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 23, 4079-4088.
5) Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, et al. : High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol (2005) 23, 7013-7023.
6) Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, et al. : Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma : results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol (2005) 23, 1984-1992.
7) Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, et al. : Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 106, 1569-1580.
8) Cheson BD : Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol (2010) 28, 3525-3530.
9) Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, et al. : First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma : results of a phase 1/2 trial. Blood (2008) 111, 5486-5495.
10) Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A ; Hx-CD20-406 Study Investigators : Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab : results from the phase 2 international study. Blood (2011) 118, 5126-5129.
11) Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, et al. : Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 30, 2183-2189.
12) Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL,et al. : Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma : results of a phaseⅡstudy. J Clin Oncol (2012) 30, 2190-2196.
13) Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, et al. : Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma : results of a phase I study. J Clin Oncol (2010) 28, 2085-2093.
14) Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, et al. : Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma : a multicenter phaseⅡstudy. J Clin Oncol (2012) 30, 837-842.
15) Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, et al. : Multicenter PhaseⅡStudy of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. J Clin Oncol (2014) 32, 1157-1163.
16) Viardot A, Goebeler M, Nopponey R, Krause SW, Kallert S, Ferstl B, Mackensen A, Rupertus K, Soekler M, Kanz L, Knop S, Topp MS, et al. : Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. ASH Annu Meet Abstr (2011) 188, 1637.
17) Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA : Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma : long-term follow-up of a phase 1/2 study. Blood (2004) 103, 4429-4431.
18) Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, et al. : Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol (2005) 23, 5044-5051.
19) Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, et al. : Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 31, 88-94.
20) Coutre SE, Leonard JP, Furman RR, Barrientos JC, Sven de Vos, Flinn IW, Schreeder MT, Wagner-Johnston ND, Sharman OP, Boyd TE, Fowler NH, Holes LM, et al. : Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3 Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) : results from a phase I study. ASH Ann Meet Abstr (2012) 120, 191.
21) Furman RR, Barrientos JC, Sharman JP, Sven De Vos, Leonard J, Coutre SE, Schreeder MT, Wagner-Johnston ND, Boyd TE, Fowler NH, Flinn IW, Boccia RV,
et al. : A phaseⅠ/Ⅱstudy of the selective phosphatidylinositol 3-kinase-delta (PI3 Kdelta) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol (2012) 30, S6518.
22) Guidetti A, Viviani S, Marchianò A, Dodero A, Farina L, Locatelli S, Russo D, Bulian P, Sorasio R, Nicola MD, Giordano L, Corradini P, et al. : Dual targeted therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in patients with relapsed/refractory lymphomas : final results of a phaseⅡtrial. ASH Annu Meet Abstr (2012) 120, 3679.
23) Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, et al. : Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol (2009) 27, 3822-3829.
24) Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, et al. : Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes : The University of Chicago phase II consortium. J Clin Oncol (2010) 28, 4740-4746.
25) Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, et al. : PhaseⅡstudy of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol (2007) 25, 1741-1746.
26) Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van't Veer MB, Milpied N, Cartron G, Pezzutto A, et al. : A phaseⅡstudy of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol (2008) 19, 247-253.
27) Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK : High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma : results of a global phase 3b expanded access program. Br J Haematol (2009) 144, 169-175.
28) Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, et al. : A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 120, 2817-2825.
29) Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, et al. : Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol (2008) 26, 4952-4957.
30) Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, et al. : Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma : a phase 1/2 clinical trial. Lancet Oncol (2012) 13,716-723.
31) Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M : Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 25, 3109-3115.
32) Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, et al. : Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 117, 5827‒5834.
33) Ogura M, Tsukasaki K, Nagai H, Uchida T, Oyama T, Suzuki T, Taguchi J, Maruyama D, Hotta T, Tobinai K : Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies. Cancer Sci (2012) 103, 1290-1295.
34) Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, et al. : Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2010) 115, 2578-2585.